Where did Seroxat Come from ?..
Who created it?..
What can we learn from its origins?…
In the middle of the 70s, reports of a new breed of antidepressant began emerging from small laboratories in Scandinavia. It was found that certain drugs like reserpine, a popular tranquillizer and anti-hypertensive treatment that depleted serotonin levels had an interesting side effect: it produced depression-like symptoms.
At the Danish firm of Ferrosan, the head of research was a man called Jørgen Buus Lassen, who supported the theory that the specific enhancement of serotonin might lift a depressive mood. He tested about 100 compounds before deciding on one that became known as paroxetine. ‘We did all the clinical trials,’ he says today from his office in Glostrup, near Copenhagen, ‘and what created most excitement among our scientists was that in some trials we saw that some patients who had been totally hopeless on the existing drugs and not at all responsive to treatment, were gradually becoming better and better. Some who had been unable to work for several years and had been in and out of psychiatric hospitals gradually came into normal life again.’
Dr Jorgen Buus Lassen wrote the first scientific paper on paroxetine in 1975, in the paper he was frank about the drugs limitations.’It didn’t work with all patients,’ he remembers. ‘In most studies we could just show that we had about the same efficacy as the older tricyclic antidepressants. We didn’t see a better effect, but we saw fewer side effects [mainly nausea].’
Dr. Jørgen Buus Lassen (Danish) received his DVM from the Royal School of Veterinary and Agriculture Science in Copenhagen. Dr. Lassen is co-founder of NeuroSearch A/S and has been the President and CEO of NeuroSearch since May 1989. He has more than 25 years’ experience within neuropharmacology and has authored or co-authored more than 30 publications, including the first paper published with respect to Paroxetin (Paxil, Seroxat), an antidepressant. From 1980 to 1988, Dr. Lassen served as Managing Director of Ferrosan A/S` research and development division, where Dr. Lassen was responsible for the expansion of all pre-clinical and clinical activities. He is chairman of the boards of NsGene A/S and Gudme Raaschou Healthcare Invest A/S and member of the boards of Bavarian Nordic A/S, Neurosearch A/S and NicOx S.A. Board member of Pharmexa since 1997. Reference is made to Pharmexa’s address.
Which is affiliated with GSK…
NeuroSearch and GlaxoSmithKline (GSK) today announced a five-year research and development alliance. The alliance comprises a number of research programmes within ion channels and the treatment of diseases of the central nervous system (CNS) including depression, anxiety, and schizophrenia. The new alliance combines NeuroSearch’s innovative research and development, and strong technology platform with GSK’s research, development, and commercial strength.
The option agreement gives GSK access to new drug candidates from NeuroSearch’s research and development within the defined area. This includes the Phase II triple monoamine re-uptake inhibitor NS2359, the Endovion programme and several other research programmes. The existing collaboration with GSK in depression disorders is integrated in the new agreement.
President CEO Jørgen Buus Lassen of NeuroSearch says, I am pleased that we were able to conclude this important strategic alliance with GSK as our two companies have had a well-functioning and trustful partnership within depression research for three years. I have a strong expectation that this extended partnership will be a major success for both companies.
GlaxoSmithKline (www.gsk.com) and the Danish company NeuroSearch (www.neurosearch.com) will collaborate to discover and develop “triple-action” monoamine reuptake inhibitors to treat depression and other mood disorders. (Development Updates).(depression and other mood disorders)(Brief Article)
For more info on Ferossan , Buus Lassen and the Origins of Paroxetine and how it came to be unleashed on an unsuspecting public see link on Seroxat link 1 (hypnotic narcotic) .. A very informative post by Rob Robinson on Paxil Progress…